Clinical trials
Clear Cell Renal Cell Carcinoma clinical trials
Below are recruiting clear cell renal cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 161 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03592472RecruitingPhase 3
Testing pazopanib with or without abexinostat for kidney cancer
This Phase 3 trial studies how well pazopanib works, and whether adding abexinostat can improve outcomes, for advanced kidney cancer that cannot be removed by surgery or has spread. You may qualify if you have clear cell renal cell carcinoma and have not already had certain targeted kidney-cancer medicines.
Phoenix, ArizonaAges 18 years+ - NCT07195682RecruitingPhase 1
Study of an experimental drug for advanced kidney cancer
This trial tests a new drug (BMS-986506) for people with advanced kidney cancer (clear cell renal cell carcinoma). It aims to see if the drug is safe and effective. Depending on the part of the study, participants may have had prior treatments or be newly diagnosed.
Boston, MassachusettsAges 18 years+ - NCT07197580RecruitingPhase 3
Study of a targeted radiation therapy for advanced kidney cancer
This trial tests a new drug called 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for people with advanced clear cell renal cell carcinoma that has returned or not responded to at least 2 prior treatments.
Sydney, New South WalesAges 18 years+ - NCT07187778RecruitingPhase 2
Kidney cancer treatment before surgery
This trial tests two drugs, alone or together, given before surgery to shrink kidney cancer tumors. It aims to see which approach works best for patients with intermediate- to high-risk clear cell renal cell carcinoma.
Houston, TexasAges 18 years+ - NCT07188896RecruitingPhase 2
Immunotherapy combinations for advanced kidney cancer
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07187869RecruitingPhase 1
Cabozantinib plus nivolumab for kidney cancer with bone spread
This study tests whether adding a drug called cabozantinib to standard nivolumab treatment helps fight kidney cancer that has spread to bone. It aims to understand how the bone environment changes during treatment.
Houston, TexasAges 18 years+ - NCT07179770RecruitingPhase 1
Belzutifan and imaging in advanced kidney cancer
This trial tests a new drug called belzutifan combined with a special imaging agent (89Zr-DFO-girentuximab) to see how they affect PET scans in people with advanced clear cell kidney cancer. It may help doctors better understand the cancer and guide treatment.
New York, New YorkAges 18 years+ - NCT07166445Recruiting
Using AI to read kidney cancer CT scans for better staging
This study uses a computer program (deep learning) to look at your kidney CT scan and tell if your cancer is more advanced (stage T3) or earlier (stage T1-T2). The goal is to help doctors plan the best treatment for you.
BeijingAges 18–85 - NCT07167329RecruitingPhase 2
Belzutifan for VHL syndrome: a real-world study
This trial tests the drug belzutifan (a pill taken by mouth) in people with VHL syndrome who have kidney or other VHL-related tumors that are growing or can be measured. The study looks at how well belzutifan works in real-world conditions and whether certain genetic factors affect how the drug works.
São Paulo, São PauloAges 14 years+ - NCT07128680RecruitingPhase 1
Immunotherapy with or without a gut bacteria pill for kidney cancer
This trial tests whether adding a live bacteria pill (EXL01) to standard immunotherapy drugs (nivolumab and ipilimumab) helps treat advanced or metastatic kidney cancer that has clear cells. You may join if you have not had prior immunotherapy and your cancer has not been treated before (except possibly after surgery).
Duarte, CaliforniaAges 18 years+ - NCT07123090RecruitingPhase 2
Triple Therapy for Advanced Kidney Cancer
This trial tests a combination of three drugs—sasanlimab (immunotherapy), palbociclib (targeted therapy), and axitinib (VEGF inhibitor)—for people with advanced kidney cancer who have not had prior treatment. It aims to see if this triple therapy is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT07101900Enrolling by invitationPhase 2
Better imaging for kidney cancer before surgery
This trial tests a new PET/CT scan that uses a special tracer to find clear cell kidney cancer. If you are scheduled for kidney tumor removal, this scan may help your surgeon see the cancer more clearly before surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07097935RecruitingPhase 1/Phase 2
Study of HS-10516 combo therapy for advanced kidney cancer
This trial tests a new combination therapy for people with advanced clear cell kidney cancer that has progressed after at least one prior treatment. It aims to see if adding HS-10516 to standard care can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07087158RecruitingPhase 2
IBR854 plus pazopanib vs pazopanib for advanced kidney cancer
This trial tests a new combination therapy (IBR854 plus pazopanib) against pazopanib alone for people with advanced clear cell kidney cancer who haven't had prior treatment. It aims to see if the combination works better.
ShanghaiAges 18 years+ - NCT07072234RecruitingPhase 1
CAR NK cell therapy for advanced clear cell kidney cancer
This trial tests a new type of immune cell therapy (CAR NK cells) that targets a protein called CD70 on kidney cancer cells. It's for people with advanced clear cell kidney cancer that hasn't responded to standard treatments.
Houston, TexasAges 18 years+ - NCT07067905RecruitingEarly Phase 1
PET scan test for glioblastoma and kidney cancer
This trial tests a new PET scan tracer called [68Ga]Ga-XT771 to see if it can better detect glioblastoma (a type of brain tumor) and clear cell renal cell carcinoma (a type of kidney cancer). If you have one of these cancers, this scan might help your doctor see the tumor more clearly.
BeijingAges 18 years+ - NCT07062549RecruitingPhase 1
New imaging agent for metastatic clear cell kidney cancer
This trial tests a new radioactive imaging agent (111In-XYIMSR-01) to see how well it finds clear cell kidney cancer that has spread. It involves a special SPECT/CT scan and may help doctors better see where the cancer is.
Baltimore, MarylandAges 18 years+ - NCT07049926RecruitingPhase 1/Phase 2
Combination therapy study for advanced kidney cancer
This trial tests new drug combinations for people with advanced kidney cancer whose disease returned after a prior immunotherapy. It's designed to find better treatment options for those who have not received other treatments for advanced disease.
San Francisco, CaliforniaAges 18–120 - NCT07043608RecruitingPhase 2
Zanzalintinib for kidney cancer that spread to bone
This trial tests a new drug called zanzalintinib for people with advanced clear cell kidney cancer that has spread to the bones (at least 3 spots). The study wants to see if this drug can help slow down or shrink the cancer. It's for patients who have already had some prior treatments.
San Francisco, CaliforniaAges 18 years+ - NCT07037004RecruitingPhase 2
Testing a gut health supplement with immunotherapy after kidney cancer surgery
This trial is testing whether adding a gut health supplement (CBM588) to the immunotherapy drug pembrolizumab can help prevent kidney cancer from returning after surgery. It is for people with certain types of kidney cancer who have not had immunotherapy before.
Duarte, CaliforniaAges 18 years+ - NCT07028125RecruitingPhase 4
Digital symptom tracking for kidney cancer treatment
This trial tests whether tracking your symptoms with a digital app can help manage side effects while you receive two medications (cabozantinib and nivolumab) for advanced clear-cell kidney cancer that hasn't been treated before.
AnnecyAges 18 years+ - NCT07018037Recruiting
TTV levels during first immunotherapy for kidney cancer
This study looks at whether a virus called TTV (torque teno virus) in the blood can help predict how well immunotherapy works for advanced kidney cancer. If you have clear cell renal cell carcinoma that has spread and are about to start your first immunotherapy, you may be able to join.
Rome, RomeAges 18 years+ - NCT07023432RecruitingPhase 2
Belzutifan vs. watchful waiting for slow-growing kidney cancer
This trial compares two approaches for people with slow-growing, metastatic clear cell kidney cancer: taking a daily pill (belzutifan) or monitoring the cancer closely without treatment. The goal is to see if starting treatment early can help control the cancer longer than waiting.
Houston, TexasAges 18 years+ - NCT06088134Recruiting
Predicting survival after kidney cancer surgery with CT scans
This study uses a computer model to analyze your CT scans and predict how long you might stay cancer-free after surgery. It aims to help doctors personalize follow-up care for clear cell kidney cancer.
Chongqing, Chongqing MunicipalityAges Any age
Hear when a new Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for clear cell renal cell carcinoma?
- Yes. Clin2 currently lists 161 recruiting clear cell renal cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clear cell renal cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clear cell renal cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.